A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
NCT00234520
·
clinicaltrials.gov ↗
COMPLETED
Status
225
Enrollment
INDUSTRY
Sponsor class
Conditions
Acromegaly
Sponsor
Ipsen